Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Desh Rakshak AushdhalayaBOM:531521 61 Days Payable is 203.53 as of Mar. 2026, which is 27% below its 10-year median of 277.59. GuruFocus rates BOM:531521 with a GF Score™ of 61/100 and a GF Value™ of ₹18.60 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Desh Rakshak Aushdhalaya ranks better than 94.82% on this metric.
The historical rank and industry rank for Desh Rakshak Aushdhalaya's Days Payable or its related term are showing as below:
BOM:531521'
s Days Payable Range Over the Past 10 Years
Min: 218.93 Med: 277.59 Max: 606.31
Current: 529.78
During the past 13 years, Desh Rakshak Aushdhalaya's highest Days Payable was 606.31. The lowest was 218.93. And the median was 277.59.
BOM:531521's Days Payable is ranked better than 94.82% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs BOM:531521: 529.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Desh Rakshak Aushdhalaya's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Desh Rakshak Aushdhalaya Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Desh Rakshak Aushdhalaya's Days Payable distribution charts can be found below:
* The bar in red indicates where Desh Rakshak Aushdhalaya's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Desh Rakshak Aushdhalaya's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Desh Rakshak Aushdhalaya (BOM:531521) has a Days Payable of 203.53 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Desh Rakshak Aushdhalaya and its competitors. This is 27% below median its historical median of 277.59. Over the past decade, Desh Rakshak Aushdhalaya's Days Payable has ranged from 218.93 to 606.31. According to the industry distribution chart, Desh Rakshak Aushdhalaya ranks #48 out of 927 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Desh Rakshak Aushdhalaya's Days Payable too high?
Desh Rakshak Aushdhalaya's current Days Payable of 203.53 is 27% below median its 10-year median of 277.59. Over the past 10 years, this metric has ranged from a low of 218.93 to a high of 606.31. The Drug Manufacturers industry median Days Payable is 90.28. Desh Rakshak Aushdhalaya's value of 203.53 is 125.4% above this industry median. Based on the distribution chart, Desh Rakshak Aushdhalaya ranks #48 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Desh Rakshak Aushdhalaya has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Desh Rakshak Aushdhalaya's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Desh Rakshak Aushdhalaya ranks #48 out of 927 companies for Days Payable. This places Desh Rakshak Aushdhalaya in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.28. Desh Rakshak Aushdhalaya's value of 203.53 is 125.4% above this benchmark. Historically, Desh Rakshak Aushdhalaya's own Days Payable has ranged from 218.93 to 606.31 over the past decade. While the company's 10-year median is 277.59 vs. the industry median of 90.28, Desh Rakshak Aushdhalaya has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Desh Rakshak Aushdhalaya's current Days Payable of 203.53 is 125.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Desh Rakshak Aushdhalaya and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Desh Rakshak Aushdhalaya's current Days Payable is 203.53, which is 27% below median its own 10-year median of 277.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Desh Rakshak Aushdhalaya stock overvalued right now?
Based on GuruFocus' analysis, Desh Rakshak Aushdhalaya (BOM:531521) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹18.60, compared to a current price of ₹31.00 — trading 66.7% above its estimated fair value. The current Days Payable is 203.53, which is 27% below median its 10-year median of 277.59 and 125.4% above the Drug Manufacturers industry median of 90.28. Desh Rakshak Aushdhalaya's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Desh Rakshak Aushdhalaya (BOM:531521), the current Days Payable is 203.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Desh Rakshak Aushdhalaya (BOM:531521) Overvalued in 2026?
Based on GuruFocus' analysis, Desh Rakshak Aushdhalaya stock appears to be overvalued.
The current stock price of ₹31.00 is trading 66.7% above its estimated GF Value™ of ₹18.60.
GuruFocus considers Desh Rakshak Aushdhalaya to be Significantly Overvalued.
Key valuation signals for BOM:531521:
Days Payable: 203.53 (27% below median its 10-year median of 277.59)
GF Value™: ₹18.60 vs. price of ₹31.00 (66.7% above fair value)
Industry Position: 125.4% above the Drug Manufacturers median (#48 of 927)
No single metric tells the full story. See the BOM:531521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Desh Rakshak Aushdhalaya Ltd manufactures and sells ayurvedic and herbal products in India. The firm offers ayurvedic patents & proprietary medicines with herbs. It provides classical and patent medicines in tablet and capsule, powder, and liquid forms. Products ranging from AmalkiChurna, Ashwagandha Tablet, TriphalaChurna, LavanaBhaskarChurna, Sat-Shilajeet, ShunthiChurna, HingwadiChurna, GasharVati, BuddhivardhakYog, Balamrit, LodhraChurna, and Others.
61GF Score
Get the complete analysis for BOM:531521
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531521 has been successfully added to your 
